Nanobiotix Files Routine 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Dec 17, 2025 · CIK: 1760854
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Nanobiotix filed a standard 6-K on 12/17/25, nothing major, just keeping the SEC updated.
AI Summary
Nanobiotix S.A. filed a Form 6-K on December 17, 2025, reporting its status as a foreign private issuer. The company, incorporated in France with its principal executive office in Paris, is subject to the 1934 Securities Exchange Act. This filing is routine and does not disclose specific financial or operational updates.
Why It Matters
This filing confirms Nanobiotix's ongoing compliance with SEC reporting requirements for foreign private issuers. It serves as a standard update for investors tracking the company's regulatory adherence.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain new material information that would typically impact risk.
Key Numbers
- 001-39777 — Commission File Number (Identifies the company's filing with the SEC)
Key Players & Entities
- Nanobiotix S.A. (company) — Registrant
- 001-39777 (dollar_amount) — Commission File Number
- December 2025 (date) — Reporting period
- Paris, France (location) — Principal executive office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have submitted or are required to submit to their security holders.
What period does this Form 6-K cover?
This Form 6-K is for the month of December 2025.
Is Nanobiotix S.A. filing its annual report on this form?
No, Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F, not this Form 6-K.
Where is Nanobiotix S.A.'s principal executive office located?
Nanobiotix S.A.'s principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
What is the SEC Act under which this filing is made?
This filing is made pursuant to the Securities Exchange Act of 1934.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-12-17 16:15:04
Filing Documents
- f6k_121725.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-25-007983.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: December 17, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer